BCAX250117P20000
- 0.00
- 0.000.00%
Bicara Therapeutics Newsroom
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Analyst Ratings
H.C. Wainwright Initiates Bicara Therapeutics(BCAX.US) With Buy Rating, Announces Target Price $42
Express News | Bicara Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $42
Promising Potential of Bicara Therapeutics' Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial Results
Bicara Therapeutics Reports Strong IPO and Clinical Advancements
Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $47
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36
Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $36
Express News | Bicara Therapeutics Inc : Morgan Stanley Raises Target Price to $36 From $35
Bicara Therapeutics | 10-Q: Quarterly report
TD Cowen Maintains Bicara Therapeutics(BCAX.US) With Buy Rating
Promising Prospects for Bicara Therapeutics: Buy Rating on Ficerafusp's Innovative Approach
Bicara Therapeutics | 8-K: Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Bicara Therapeutics Q3 2024 GAAP EPS $(1.60) Misses $(0.44) Estimate
Bicara Therapeutics Has About $521M in Cash, Cash Equivalents >BCAX
Bicara Therapeutics 3Q Loss/Shr $1.60 >BCAX
Express News | Bicara Therapeutics: Cash and Cash Equivalents Expected to Fund Operations Into First Half of 2029
Express News | Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update